EUVIMEDEUVIMED entdecken
Open Access

The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non‐AML myeloid neoplasms

Hatem Kaseb, Valeria Visconte iD, Daniel S Socha, Genevieve M Crane iD, Lisa Durkin, James R Cook, Jaroslaw P Maciejewski, Eric D Hsi iD, Heesun J Rogers iD

Genes, Chromosomes and Cancer · 2023

DOI: 10.1002/gcc.23139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, Chromosomes and Cancer, 2023. Verfasst von Hatem Kaseb und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Central Florida College of Medicine, Orlando, Florida, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myeloproliferative Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NPM1 mutated non‐AML myeloid neoplasms (MN; T p. L287F; 65%) than frameshift insertion/duplication (35%) with median variant allele frequency (VAF; 9.7%, range 5.1%–49.8%). Mutated NPM1 by IHC showed cytoplasmic positivity in 48% and positivity was associated with higher VAF. The median overall survival (OS) in this cohort was 70 months. Nine patients (26%) progressed to AML. OS in patients who progressed to AML was significantly shorter than the one of patients without progression to AML (OS 20 vs. 128 months, respectively, log rank p = 0.05). NPM1 mutated non‐AML MN patients commonly had cytopenias, dysplasia, normal karyotype, mutations in multiple genes, and an unfavorable clinical outcome, including progression to AML. Our data demonstrated that IHC for NPM1 can be a useful supplementary tool to predict NPM1 mutation in some non‐AML MN; however, genetic testing cannot be replaced by IHC assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteMyeloproliferative DisordersHumansNuclear ProteinsNucleophosminImmunohistochemistryRetrospective StudiesMutation

Stichwörter der Autor:innen

NPM1 immunohistochemistryNPM1 mutationnon-AML myeloid neoplasm

Substanzen

Nuclear ProteinsNucleophosmin

Autor:innen und Institutionen

  • Department of Pathology, University of Central Florida College of Medicine, Orlando, Florida, USA.
  • Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Pathology, OhioHealth, Riverside Methodist Hospital, Columbus, Ohio, USA.
  • Department of Laboratory Medicine, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Pathology and Laboratory Medicine, Wake Forest School of Medicine, Wake Forest Baptist Health, Winston-Salem, North Carolina, USA.

ORCID-Profile: Valeria Visconte, Genevieve M Crane, Eric D Hsi, Heesun J Rogers

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Kaseb, H., Visconte, V., Socha, D. S., Crane, G. M., Durkin, L., Cook, J. R., Maciejewski, J. P., Hsi, E. D., & Rogers, H. J. (2023). The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non‐AML myeloid neoplasms. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.23139

Vancouver

Kaseb H, Visconte V, Socha DS, Crane GM, Durkin L, Cook JR, et al. The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non‐AML myeloid neoplasms. Genes, Chromosomes and Cancer. 2023. doi:10.1002/gcc.23139

BibTeX
@article{Kaseb2023,
  author = {Kaseb, Hatem and Visconte, Valeria and Socha, Daniel S and Crane, Genevieve M and Durkin, Lisa and Cook, James R and Maciejewski, Jaroslaw P and Hsi, Eric D and Rogers, Heesun J},
  title = {The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non‐AML myeloid neoplasms},
  journal = {Genes, Chromosomes and Cancer},
  year = {2023},
  doi = {10.1002/gcc.23139}
}
Kostenlos starten →